Avi I. Einzig

2.1k total citations
34 papers, 1.7k citations indexed

About

Avi I. Einzig is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Dermatology. According to data from OpenAlex, Avi I. Einzig has authored 34 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 6 papers in Dermatology. Recurrent topics in Avi I. Einzig's work include Cancer Treatment and Pharmacology (22 papers), Colorectal Cancer Treatments and Studies (10 papers) and Gastric Cancer Management and Outcomes (6 papers). Avi I. Einzig is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Colorectal Cancer Treatments and Studies (10 papers) and Gastric Cancer Management and Outcomes (6 papers). Avi I. Einzig collaborates with scholars based in United States, Italy and Japan. Avi I. Einzig's co-authors include Peter H. Wiernik, Janice P. Dutcher, Richard B. Lipton, Carolyn D. Runowicz, Gary L. Goldberg, Edward L. Schwartz, J Strauman, Al B. Benson, Herbert H. Schaumburg and Alan R. Berger and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer.

In The Last Decade

Avi I. Einzig

34 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Avi I. Einzig United States 20 1.2k 411 382 197 175 34 1.7k
Christine M. Kearns United States 15 884 0.7× 237 0.6× 223 0.6× 76 0.4× 66 0.4× 22 1.3k
David R. Gandara United States 24 834 0.7× 507 1.2× 573 1.5× 405 2.1× 47 0.3× 47 1.6k
Taher Al‐Tweigeri Saudi Arabia 24 1.7k 1.4× 354 0.9× 619 1.6× 183 0.9× 47 0.3× 61 2.5k
Peter Ang Singapore 21 730 0.6× 225 0.5× 469 1.2× 63 0.3× 125 0.7× 57 1.6k
R. Kath Germany 18 454 0.4× 176 0.4× 433 1.1× 187 0.9× 42 0.2× 55 1.3k
P Wülfing Germany 22 576 0.5× 191 0.5× 773 2.0× 153 0.8× 90 0.5× 47 1.7k
Michael A. Levesque Canada 19 407 0.3× 336 0.8× 405 1.1× 71 0.4× 68 0.4× 32 1.2k
Haruhiko Makino Japan 20 673 0.6× 345 0.8× 431 1.1× 142 0.7× 165 0.9× 83 1.6k
Elba A. Turbat‐Herrera United States 22 308 0.3× 213 0.5× 735 1.9× 276 1.4× 46 0.3× 80 1.5k
Yoshiyasu Nakamura Japan 25 528 0.4× 398 1.0× 650 1.7× 203 1.0× 17 0.1× 71 1.6k

Countries citing papers authored by Avi I. Einzig

Since Specialization
Citations

This map shows the geographic impact of Avi I. Einzig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Avi I. Einzig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Avi I. Einzig more than expected).

Fields of papers citing papers by Avi I. Einzig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Avi I. Einzig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Avi I. Einzig. The network helps show where Avi I. Einzig may publish in the future.

Co-authorship network of co-authors of Avi I. Einzig

This figure shows the co-authorship network connecting the top 25 collaborators of Avi I. Einzig. A scholar is included among the top collaborators of Avi I. Einzig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Avi I. Einzig. Avi I. Einzig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ramalingam, Sakkaraiappan, et al.. (2004). Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study. Cancer Chemotherapy and Pharmacology. 53(5). 439–444. 12 indexed citations
2.
3.
Belani, Chandra P., Avi I. Einzig, Philip Bonomi, et al.. (2000). Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Annals of Oncology. 11(6). 673–678. 42 indexed citations
4.
Einzig, Avi I., et al.. (1999). Non-Hodgkin Lymphoma in Acquired Immunodeficiency Syndrome Manifesting as Bilateral Hypopyon. American Journal of Clinical Oncology. 22(1). 82–83. 3 indexed citations
5.
O’Boyle, Kevin, Edward L. Schwartz, Avi I. Einzig, et al.. (1997). Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids. Cancer. 79(5). 1022–1030. 8 indexed citations
6.
Sklarin, Nancy T., et al.. (1997). A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. Investigational New Drugs. 15(3). 235–246. 9 indexed citations
7.
Einzig, Avi I., et al.. (1996). Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Medical Oncology. 13(2). 111–117. 25 indexed citations
8.
9.
Einzig, Avi I., Stuart R. Lipsitz, Peter H. Wiernik, & Al B. Benson. (1995). Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). Investigational New Drugs. 13(3). 223–227. 30 indexed citations
10.
Walpole, Euan, Rasim Gucalp, Avi I. Einzig, et al.. (1993). Survival After Phase II Treatment of Advanced Renal Cell Carcinoma with Taxol or High-Dose Interleukin-2. Journal of Immunotherapy. 13(4). 275–281. 20 indexed citations
11.
Sparano, Joseph A., Scott Wadler, Robert B. Diasio, et al.. (1993). Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation.. Journal of Clinical Oncology. 11(8). 1609–1617. 25 indexed citations
12.
Runowicz, Carolyn D., Peter H. Wiernik, Avi I. Einzig, Gary L. Goldberg, & Susan Band Horwitz. (1993). Taxol in ovarian cancer. Cancer. 71(S4). 1591–1596. 52 indexed citations
13.
Kaplan, Jerry G., Avi I. Einzig, & Herbert H. Schaumburg. (1993). Taxol causes permanent large fiber peripheral nerve dysfunction: a lesson for preventative strategies. Journal of Neuro-Oncology. 16(2). 105–107. 10 indexed citations
14.
Einzig, Avi I., et al.. (1992). Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.. Journal of Clinical Oncology. 10(11). 1748–1753. 216 indexed citations
15.
Einzig, Avi I., Peter H. Wiernik, & Edward L. Schwartz. (1992). Taxol: A new agent active in melanoma and ovarian cancer. Cancer treatment and research. 58. 89–100. 22 indexed citations
16.
Einzig, Avi I., et al.. (1991). Phase II Trial of Taxol in Patients with Metastatic Renal Cell Carcinoma. Cancer Investigation. 9(2). 133–136. 42 indexed citations
17.
Hirsch, Bruce E., et al.. (1991). Instillation of Vancomycin into a Cerebrospinal Fluid Reservoir to Clear Infection: Pharmacokinetic Considerations. The Journal of Infectious Diseases. 163(1). 197–200. 31 indexed citations
18.
Einzig, Avi I., et al.. (1991). A phase II study of taxol in patients with malignant melanoma. Investigational New Drugs. 9(1). 59–64. 152 indexed citations
19.
Lipton, Richard B., Stuart C. Apfel, Janice P. Dutcher, et al.. (1989). Taxol produces a predominantly sensory neuropathy. Neurology. 39(3). 368–368. 250 indexed citations
20.
Wadler, Scott, et al.. (1988). Phase II Trial of Recombinant Alpha-2b-Interferon and Low-Dose Cyclophosphamide in Advanced Melanoma and Renal Cell Carcinoma. American Journal of Clinical Oncology. 11(1). 55–59. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christine M. Kearns Breakdown of academic impact, for papers by David R. Gandara Breakdown of academic impact, for papers by Taher Al‐Tweigeri Breakdown of academic impact, for papers by Peter Ang Breakdown of academic impact, for papers by R. Kath Breakdown of academic impact, for papers by P Wülfing Breakdown of academic impact, for papers by Michael A. Levesque Breakdown of academic impact, for papers by Haruhiko Makino Breakdown of academic impact, for papers by Elba A. Turbat‐Herrera Breakdown of academic impact, for papers by Yoshiyasu Nakamura
Rankless by CCL
2026